Janvia 50


Janvia 50


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)






Monotherapy and Combination Treatment: Sitagliptin is demonstrated as an aide to count calories and work out to make strides glycemic control in grown-ups with sort 2 diabetes mellitus.
Important Restrictions of Utilize: Sitagliptin ought to not be utilized in patients with sort 1 diabetes or for the treatment of diabetic ketoacidosis, because it would not be compelling in these settings. Sitagliptin has not been examined in patients with a history of pancreatitis. It is obscure whether patients with a history of pancreatitis are at expanded hazard for the advancement of pancreatitis whereas utilizing Sitagliptin.


Sitagliptin may be a DPP-4 inhibitor, which is accepted to apply its activities in patients with sort 2 diabetes by abating the inactivation of incretin hormones. Concentrations of the dynamic intaglio hormones are expanded by Sitagliptin, subsequently expanding and drawing out the activity of these hormones. Incretin hormones, counting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are discharged by the digestive tract all through the day, and levels are expanded in reaction to a dinner. These hormones are quickly inactivated by the protein, DPP-4. The incretins are part of an endogenous framework included within the physiologic direction of glucose homeostasis. When blood glucose concentrations are typical or raised, GLP-1 and GIP increment affront union and discharge from pancreatic beta cells by intracellular signaling pathways including cyclic AMP. GLP-1 moreover brings down glucagon discharge from pancreatic alpha cells, driving to diminished hepatic glucose generation. By expanding and drawing out dynamic incretin levels, Sitagliptin increments affront discharge and diminishes glucagon levels within the circulation in a glucose-dependent way. Sitagliptin illustrates selectivity for DPP-4 and does not restrain DPP-8 or DPP-9 action in vitro at concentrations approximating those from helpful measurements


Dosage and Administration

The prescribed measurements of sitagliptin is 50 mg twice a day and 100 mg once day by day. Sitagliptin can be taken with or without nourishment.


Impacts of sitagliptin on other Drugs: Sitagliptin did not definitively modify the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or verbal contraceptive.

Digoxin: Sitagliptin marginally increments the cruel of Digoxin concentration. Be that as it may, no dosage alteration of either sedate is required.


History of a genuine extreme touchiness response to sitagliptin, such as anaphylaxis or angioedema.


Side Effects

The foremost common unfavorable responses incorporate cerebral pain, upper respiratory tract contamination and nasopharyngitis. Hypoglycemia may happen in patients treated with the combination to Sitagliptin and sulfonylurea and include on to affront.


Pregnancy & Lactation

Pregnancy Category B. Generation considers have been performed in rats and rabbits. Since creature generation ponders are not continuously prescient of human reaction, this medicate ought to be utilized amid pregnancy as it were on the off chance that clearly required. Sitagliptin is emitted within the drain of lactating rats at drain to plasma ratio of 4:1. It isn’t known whether sitagliptin is excreted in human drain. Since numerous drugs are excreted in human drain, caution ought to be worked out when sitagliptin is managed to a nursing lady.


Precautions & Warnings

On the off chance that pancreatitis is suspected, sitagliptin ought to expeditiously be suspended and suitable administration ought to be initiated.

Use in Patients with Renal Inadequate: Measurement alteration is suggested in patients with direct or serious renal lacking and in patients with ESRD requiring hemodialysis or peritoneal dialysis.
Utilize with drugs known to cause Hypoglycemia: When sitagliptin is utilized in combination treatment measurement alteration of sulfonylurea or affront may be required to diminish the chance of hypoglycemia.
Hypersensitivity Responses: There have been post-marketing reports of genuine extreme touchiness responses in patients treated with sitagliptin. These responses incorporate anaphylaxis, angioedema, and exfoliative skin conditions counting Stevens-Johnson disorder. On the off chance that a extreme touchiness response is suspected, suspend sitagliptin, survey for other potential causes for the occasion, and organized elective treatment for diabetes.

Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor


Storage Conditions

Store below 25°C in a dry place away from light. Keep the medicines in a safe place, out of the reach of children. Do not use later than the date of expiry. To be dispensed only on the prescription of a registered physician


Pharmaceutical Name

ACME Laboratories Ltd.